Nomura Reiterates “Buy” Rating for Neurocrine Biosciences (NBIX)
Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “buy” rating reaffirmed by Nomura in a research note issued on Thursday, AnalystRatingsNetwork reports. They currently have a $23.00 price target on the stock. Nomura’s price target would indicate a potential upside of 66.91% from the stock’s previous close.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded down 2.98% during mid-day trading on Thursday, hitting $13.37. The stock had a trading volume of 170,400 shares. Neurocrine Biosciences has a 52 week low of $8.57 and a 52 week high of $20.29. The stock’s 50-day moving average is $15.59 and its 200-day moving average is $13.48. The company’s market cap is $906.4 million.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings data on Thursday, February 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.79 million. During the same quarter in the previous year, the company posted $0.14 earnings per share. The company’s revenue for the quarter was down 96.7% on a year-over-year basis. Analysts expect that Neurocrine Biosciences will post $-0.87 EPS for the current fiscal year.
NBIX has been the subject of a number of other recent research reports. Analysts at TheStreet downgraded shares of Neurocrine Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, April 16th. Separately, analysts at Oppenheimer raised their price target on shares of Neurocrine Biosciences from $15.00 to $19.00 in a research note on Monday, February 10th. They now have an “outperform” rating on the stock. Finally, analysts at Roth Capital raised their price target on shares of Neurocrine Biosciences from $22.00 to $24.00 in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $20.18.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.